DI SCALA, GERARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.112
EU - Europa 536
AS - Asia 133
Totale 1.781
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.109
IT - Italia 158
IE - Irlanda 124
SE - Svezia 90
PL - Polonia 66
HK - Hong Kong 65
CH - Svizzera 34
CN - Cina 34
RU - Federazione Russa 27
JO - Giordania 21
DE - Germania 12
GB - Regno Unito 9
VN - Vietnam 6
AT - Austria 5
FR - Francia 5
UA - Ucraina 4
CA - Canada 3
KR - Corea 3
IN - India 2
NL - Olanda 2
SG - Singapore 1
TR - Turchia 1
Totale 1.781
Salva come PNG Salva come JPEG
Città #
Fairfield 171
Dublin 124
Ashburn 112
Chandler 110
Seattle 84
Houston 76
Woodbridge 76
Warsaw 66
Lawrence 53
Altamura 52
Cambridge 52
Wilmington 51
Hong Kong 36
Bern 33
Buffalo 30
Princeton 30
Boston 26
Florence 24
Moscow 24
Ann Arbor 22
Beijing 15
New York 14
San Diego 11
Boardman 10
Kent 10
Rome 8
Shanghai 8
Falls Church 7
Medford 7
Redwood City 7
Bologna 6
Dong Ket 6
Norwalk 5
Vienna 5
Hillsboro 4
Jinan 4
Napoli 4
Washington 4
Milan 3
Padova 3
Redmond 3
Rieti 3
Andover 2
Bari 2
Capannori 2
Castelliri 2
Guangzhou 2
London 2
Naaldwijk 2
Rho 2
Romainville 2
Saint-Fons 2
Seoul 2
Taiyuan 2
Toronto 2
Acton 1
Arezzo 1
Bad Kreuznach 1
Barletta 1
Esslingen am Neckar 1
Forlì 1
Hefei 1
Hounslow 1
Laurel 1
Leawood 1
Los Angeles 1
Misano Adriatico 1
Montespertoli 1
Montréal 1
New Bedfont 1
New Delhi 1
Ourton 1
Pisa 1
Pune 1
Singapore 1
St Petersburg 1
Taizhou 1
Trumbull 1
Wandsworth 1
Xian 1
Totale 1.450
Salva come PNG Salva come JPEG
Nome #
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study 137
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome 102
Intravenous immunoglobulin therapy: a snapshot for the internist. 94
A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis 93
Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects 89
Practice parameters for sublingual immunotherapy 89
Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement 74
Vascular Behçet's syndrome: an update 70
The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review 68
Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: A multicentre study 65
Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study 65
Impact of cardiovascular and immunologic variables on subclinical carotid atherosclerosis in subjects with anti-phospholipid antibodies 64
Behçet's disease as a cause of cerebral sinus vein thrombosis: an emerging role 59
The Presence of Uveitis Is Associated With a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease 58
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors 57
Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: A cross-sectional study 57
Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease 56
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 56
Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis 53
Predictors of Sustained Clinical Response in Patients With Behçet's Disease-Related Uveitis Treated With Infliximab and Adalimumab 53
Erratum: Management of adult-onset Still's disease with interleukin-1 inhibitors: Evidence- And consensus-based statements by a panel of Italian experts 45
Clinical profile and evolution of patients with juvenile-onset Behçet’s syndrome over a 25-year period: insights from the AIDA network 38
Subclinical and Clinical Atherosclerosis in Rheumatoid Arthritis: Results From the 3-year, Multicentre, Prospective, Observational GIRRCS (Gruppo Italiano Di Ricerca in Reumatologia Clinica E Sperimentale) Study 37
Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis 36
Correction to: Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease (Clinical Rheumatology, (2017), 36, 9, (2063-2069), 10.1007/s10067-017-3627-4) 34
Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease 31
Prompt Clinical Response to Secukinumab in Patients With Axial Spondyloarthritis: Real Life Observational Data From Three Italian Referral Centers 31
Different Drug Survival of First Line Tumour Necrosis Factor Inhibitors in Radiographic and Non-Radiographic Axial Spondyloarthritis: A Multicentre Retrospective Survey 29
Low-dose tocilizumab for relapsing giant cell arteritis in the elderly, fragile patient: Beyond the GiACTA trial 28
Prevalence and clinical associations of ultrasound-confirmed enthesitis in systemic lupus erythematosus 24
Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study 23
ROS-driven structural and functional fibrinogen modifications are reverted by interleukin-6 inhibition in Giant Cell Arteritis 10
Totale 1.825
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.321
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201910 0 0 0 0 0 0 0 0 0 0 5 5
2019/2020391 8 19 1 19 44 43 54 48 54 30 31 40
2020/2021304 26 27 21 26 55 26 12 13 36 25 23 14
2021/2022235 1 8 32 12 2 12 3 30 14 10 47 64
2022/2023595 54 164 20 14 30 88 71 29 62 8 17 38
2023/2024262 12 24 37 19 24 40 16 53 4 18 15 0
Totale 1.825